Gland Pharma Limited (BSE: 543245, NSE: GLAND) has signed a strategic Manufacturing and Supply Agreement with a leading global pharmaceutical company to develop, manufacture and supply a portfolio of sterile injectable products for international markets. The agreement covers 55 products across three manufacturing sites, with annual revenue potential of approximately $90 million to $100 million once all products are commercialised.
The partnership will make Gland Pharma an end-to-end contract development and manufacturing organisation (CDMO) partner for both marketed products and products under development. The scope includes technology transfer, process development, scale-up, validation, commercial manufacturing and long-term supply.
The product portfolio includes oncology and non-oncology injectables in vial, lyophilised vial, ampoule and pre-filled syringe formats. It covers both complex and conventional formulations, allowing Gland Pharma to leverage its capabilities in product development, manufacturing, quality and regulatory support.
Technology transfer activities are expected to be completed within two years, with revenue contribution expected to begin from calendar year 2029. The agreement also provides scope for additional products to be added to the portfolio, potentially increasing the long-term value of the partnership.
The agreement strengthens Gland Pharma’s CDMO business and expands its role in supporting global pharmaceutical companies across multiple stages of the product lifecycle. Its integrated manufacturing network and experience in sterile injectables are expected to support the partner’s requirements from technology transfer through commercial production and ongoing supply.
Commenting on the agreement, Srinivas Sadu, Executive Chairman, Gland Pharma Limited, said, “We are pleased to enter into this strategic collaboration. The partnership highlights the confidence global pharmaceutical companies place in Gland Pharma’s development, technology transfer, manufacturing and supply capabilities. The agreement provides meaningful long-term revenue visibility, supports expansion of our CDMO business and creates a strong foundation for future growth.”
Gland Pharma was established in Hyderabad in 1978 and has grown from a contract manufacturer of small-volume liquid parenteral products into an injectable-focused pharmaceutical company with operations and customers across global markets.The company follows a CDMO and business-to-business model and has capabilities spanning the development, manufacturing and supply of sterile injectable products. Its portfolio includes vials, ampoules, pre-filled syringes, lyophilised products, dry powders, infusions, oncology products and ophthalmic solutions.
